This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Interestingly, the 340B law was actually included in a veterans healthcare bill (the Veterans Health Care Act) that also established a separate drug pricing program for veterans hospitals. It also raised the DSH payment cap for some rural and small urban hospitals to 12%. 2015: PhRMA won a lawsuit against HRSA regarding orphan drugs.
Kristen Dowd Director, Pharmacy Management Services, Omnicell If the 2022 NASP (National Association of Specialty Pharmacy) Annual Meeting and Expo is any indication, we are approaching a time when specialty pharmacy simply becomes pharmacy – when complex, high-touch biologics become nearly as ubiquitous as their broad-spectrum counterparts.
One of the growing complaints that I have heard from 340B providers over the past decade is that the benefit of the program is being transferred from safety net hospitals, health centers and clinics to private payers. Congress did not intend for 340B savings to subsidize for-profit insurance companies and pharmacy benefit managers.”
Although hospital groups were not successful in their motion to intervene in the lawsuit between AstraZeneca and U.S. Hospital groups are calling on Secretary Becerra to impose civil monetary penalties for each instance of overcharges and to require that the pharmaceutical manufacturers refund covered entities for overpayments.
In this most recent EO, the President targeted not one, but three of the largest sectors of healthcare—hospitals, health plans, and pharmaceutical companies. Health Insurance The EO directs HHS to standardize options in the National Health Insurance Marketplace (HealthCare.gov) so that people can comparison shop more easily.
Ken Perez Vice President, Healthcare Policy and Government Affairs, Omnicell How much health policy change can the Biden administration effect during the next four years? Which way will the political winds blow in Washington, D.C.? and Senate Minority Leader Mitch McConnell (R-Ky.) 3) The Supreme Court Ruling on Texas v.
Nonetheless, in the spirit of the New Year, here are three predictions in the 340B drug pricing area for 2022: Supreme Court Case on Medicare Part B Reimbursement: 340B Hospitals Win Battle but Not War Oral arguments in the U.S. Supreme Court case of American Hospital Association v. Becerra took place on Nov. ” Kavanaugh said.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content